Confirmed

Cancer Biotherapeutics

9 names are moving together; 78% are participating in the current session.

Co-movement

Observed member paths adjusted against SPY. Shading marks the latest observation window.

Members

TICKER	Company	Sector	Today	Observed activity
CTMX	CytomX Therapeutics, Inc.	Healthcare	-1.7%	Group member
RARE	Ultragenyx Pharmaceutical Inc.	Healthcare	-1.8%	Group member
CBIO	Crescent Biopharma, Inc.	Healthcare	-9.2%	Most structurally connected
VSTM	Verastem, Inc.	Healthcare	-2.8%	Group member
TENX	Tenax Therapeutics, Inc.	Healthcare	-8.9%	Group member
MIRM	Mirum Pharmaceuticals, Inc.	Healthcare	-2.5%	Group member
ASMB	Assembly Biosciences, Inc.	Healthcare	-1.8%	Group member
ARTV	Artiva Biotherapeutics, Inc.	Healthcare	-7.3%	Group member
MLYS	Mineralys Therapeutics, Inc.	Healthcare	-2.7%	Group member

Why we believe this

Cohort

9 names

Participation

78% this session

Observed history

1 daily builds

Filing coverage

9/9 members

product pipeline / R&D affecting expense

“e Agreement for CR-002; • $78.2 million of research and development expense related to licensing fees for CR-003 under our agreement with Kelun; • $2.2 million of external research and discovery expense, including $2.0 million due to Paragon for services rendered under the ADC Paragon Option Agreement for discovery efforts related to Former CR-003; and • $16.5 million of personnel-related costs related to recruiting costs, salaries, benefits, and other compensation-related costs, including share-based compensation expense of $6.6 million.”
CBIO 10-K

credit / rates affecting interest expense

“No interest expense was recognized for the three months ended March 31, 2026 due to the conversion of the Convertible Notes immediately prior to the closing of the Merger.”
CBIO 10-Q

product pipeline / R&D

“Net cash used in investing activities for the twelve months ended December 31, 2025 were primarily attributable to $72.0 million for the purchase of a research and development license, as well as purchases of property and equipment associated with the build-out of the sublease of office space located in Waltham, Massachusetts.”
CBIO 10-K

This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.

Connected, outside the group

GILD

ASMBcustomer · Not moving with the group now

Filing receipt · GILD / ASMB

“R&D Services At the commencement of the arrangement and after subsequent amendments, the Company concluded Gilead was a customer and accordingly, the Gilead Collaboratio…”
ASMB · customer

PFE

VSTMsupplier · Moving with the group now · 115 min observed

Filing receipt · PFE / VSTM

“Pfizer provided us with an initial quantity of clinical supplies of one of the products for an agreed upon price.”
VSTM · supplier

MRK

CBIOcompetitor · Not moving with the group now

Filing receipt · MRK / CBIO

“First, we are developing CR-001, which we refer to as a PD-1 x VEGF bispecific antibody because it is designed to bind both the PD-1 immune checkpoint (“PD-1”) and Vascu…”
CBIO · competitor

TAK

MIRMcustomer · Not moving with the group now

Filing receipt · TAK / MIRM

“We expect that total product sales of our approved medicines will continue to increase on an annual basis; however, due to large periodic orders from Takeda and our dist…”
MIRM · customer

REGN

RAREpartner · Not moving with the group now

Filing receipt · REGN / RARE

“If we, our collaborators, such as KKC or Regeneron, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulator…”
RARE · partner

History

2026-07-139 names in the durable cohort